ACAD
33.72
+1.51
+4.69%
AEMD
2.25
-0.02
-0.88%
APRI
1.22
+0.02
+1.67%
ARNA
1.36
+0.06
+4.62%
ATEC
1.96
-0.04
-2.00%
CNAT
7.64
+0.1
+1.33%
CRXM
0.2
0.00
-2.20%
CYTX
1.1
+0.09
+8.91%
DXCM
74.89
-0.34
-0.45%
GNMK
12.55
+0.05
+0.40%
HALO
13.39
+0.11
+0.79%
ILMN
180.2
+4.91
+2.80%
INNV
0.095
-0.004
-3.965%
INO
6.53
+0.26
+4.15%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
105.12
+0.73
+0.70%
LPTN
2.93
0.00
0.00%
MBVX
2.01
+0.12
+6.35%
MEIP
1.56
-0.01
-0.64%
MNOV
5.43
-0.4
-6.86%
MRTX
4.4
+0.15
+3.53%
MSTX
0.138
+0.008
+6.2308%
NBIX
51.78
+0.68
+1.33%
NUVA
76.35
+1.33
+1.77%
ONCS
1.17
-0.03
-2.4917%
ONVO
2.73
+0.02
+0.74%
OREX
2.98
+0.09
+3.11%
OTIC
12.5
+0.15
+1.21%
QDEL
23.5
-0.06
-0.25%
RCPT
231.96
0.00
0.00%
RGLS
1.4
0.00
0.00%
RMD
70.74
+0.9
+1.29%
SPHS
2.61
+0.01
+0.38%
SRNE
1.75
-0.05
-2.78%
TROV
0.88
+0.052
+6.2832%
VICL
2.369
+0.109
+4.823%
VOLC
18
0.00
0.00%
ZGNX
10.6
-0.1
-0.93%
ACAD
33.72
+1.51
+4.69%
AEMD
2.25
-0.02
-0.88%
APRI
1.22
+0.02
+1.67%
ARNA
1.36
+0.06
+4.62%
ATEC
1.96
-0.04
-2.00%
CNAT
7.64
+0.1
+1.33%
CRXM
0.2
0.00
-2.20%
CYTX
1.1
+0.09
+8.91%
DXCM
74.89
-0.34
-0.45%
GNMK
12.55
+0.05
+0.40%
HALO
13.39
+0.11
+0.79%
ILMN
180.2
+4.91
+2.80%
INNV
0.095
-0.004
-3.965%
INO
6.53
+0.26
+4.15%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
105.12
+0.73
+0.70%
LPTN
2.93
0.00
0.00%
MBVX
2.01
+0.12
+6.35%
MEIP
1.56
-0.01
-0.64%
MNOV
5.43
-0.4
-6.86%
MRTX
4.4
+0.15
+3.53%
MSTX
0.138
+0.008
+6.2308%
NBIX
51.78
+0.68
+1.33%
NUVA
76.35
+1.33
+1.77%
ONCS
1.17
-0.03
-2.4917%
ONVO
2.73
+0.02
+0.74%
OREX
2.98
+0.09
+3.11%
OTIC
12.5
+0.15
+1.21%
QDEL
23.5
-0.06
-0.25%
RCPT
231.96
0.00
0.00%
RGLS
1.4
0.00
0.00%
RMD
70.74
+0.9
+1.29%
SPHS
2.61
+0.01
+0.38%
SRNE
1.75
-0.05
-2.78%
TROV
0.88
+0.052
+6.2832%
VICL
2.369
+0.109
+4.823%
VOLC
18
0.00
0.00%
ZGNX
10.6
-0.1
-0.93%
Home » Archive by Category

Syndication

Sr. Principal Scientist, Analytical & Viral Assay Development – Pfizer Inc. – La Jolla, CA

April 24, 2017 – 6:05 am

PhD in Chemistry, Biochemistry, or related discipline with at least 8 years of pharmaceutical or biotechnology industry experience is necessary….From Indeed – Mon, 24 Apr 2017 14:05:14 GMT – View all La Jolla jobs

ViaCyte to Present at ARM’s 5th Annual Cell & Gene Therapy Investor Day in Boston

April 24, 2017 – 5:00 am

ViaCyte to also present at World Advanced Therapies and Regenerative Medicine Congress in London

SAN DIEGO, April 24, 2017 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company, today announced two presentations on April 27 at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day in Boston.  ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes.  The company’s lead PEC-Direct product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.  The related PEC-Encap product candidate in development has the potential to provide a functional cure for essentially all patients with type 1 diabetes as well as become an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.  

A live webcast at the 5th Annual Cell & Gene Therapy Investor Day will be available at the time of the presentations here: http://www.arminvestorday.com/webcast.

ViaCyte will also present at the upcoming World Advanced Therapies and Regenerative Medicine Congress in London on May 19.

Details of the presentations are as follows:

Event:

5th Annual Cell & Gene Therapy Investor Day

Speaker:

Dr. Paul Laikind, President and Chief Executive Officer

Panel:

Cell Therapy Beyond Oncology: Where Does the Greatest Potential Lie?

Date/Time:

April 27, 10:25 AM EDT

Location: 

The State Room, Boston

Event: 

5th Annual Cell & Gene Therapy Investor Day

Speaker:

Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Fireside Chat:

Hosted by Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray

Date/Time:

April 27, 5:00 PM EDT

Location: 

The State Room, Boston

Event: 

World Advanced Therapies and Regenerative Medicine Congress

Speaker:

Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Date/Time:

May 19, 9:40 AM BST

Location: 

Business Design Centre, London

For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two products in development.  The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device that allows direct vascularization of the implant in order to insure a robust and consistent engraftment and is being developed for type 1 diabetes patients who have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia.  The PEC-Encap™ (also known as VC-01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.  For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.

 

 

SOURCE ViaCyte, Inc.

Pfenex To Report First Quarter 2017 Results and Provide Business Update on Monday, May 8, 2017

April 24, 2017 – 4:00 am

SAN DIEGO, April 24, 2017 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX) announced today that its first quarter 2017 financial results will be released on Monday, May 8, 2017, after the market close.  At 4:30 pm Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update.  A press release outlining the financial results and business update will be publicly distributed prior to the call.

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call.  A replay of the conference call will be available approximately one hour after the call until May 15, 2017.  To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10106167. The conference call will also be available as a webcast.  To access the webcast link please log on to www.pfenex.com.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com/), our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidates are PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis, and PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, therapeutic equivalents to reference listed drug products, and next generation biologics.

 

SOURCE Pfenex Inc.

Director, Clinical Operations – Xencor – San Diego, CA

April 24, 2017 – 2:37 am

Is an innovative biotechnology company located in the Los Angeles area (near Pasadena) and in San Diego. We have a very deep drug development pipeline including…From BioSpace.com – Mon, 24 Apr 2017 10:37:31 GMT – View all San Diego jobs

postdoctoral fellow (Sorernto Valley)

April 23, 2017 – 9:43 pm

Seek highly motivated fresh Ph.D. graduates, or second to the fifth years postdoctoral research; proven track record of refereed publications; Cellular and Molecular immunology: immune cell separation and four to six color FACS, confocal microscopy, […

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

April 23, 2017 – 9:27 pm

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for…

[[Click headline to continue reading.]]

Associate Cell Biologist (carlsbad)

April 23, 2017 – 10:14 am

ScienCell Research Laboratories (http://www.sciencellonline.com) is a biotechnology company whose mission is the research and development of cell and cell-related products for experimental and therapeutic use. Due to the rapid expending of our busine […

Clinical Research Associate – Green Key Resources – San Diego, CA

April 23, 2017 – 1:00 am

2+ years as a Regional CRA at a Pharma, Biotech or CRO required. Seeking a Regional Clinical Research Associate for a Pharmaceutical company that specializes in…From Indeed – Sun, 23 Apr 2017 09:00:54 GMT – View all San Diego jobs

Quality Assurance and Safety Manager – Growing Biotech Firm (Sorrento Valley)

April 22, 2017 – 10:42 pm

Quality Manager
Summary:
Immediate opening for a Quality Manager for a small contract research and manufacturing BIOTECH company. We are growing and are expanding our labs. The Quality and Safety Manager is responsible for implementation of the qua […

QC Lab Technician – Growing Biotech Firm (Sorrento Valley)

April 22, 2017 – 10:36 pm

Full Time — QC Lab Technician
*** Perfect for lab technicians looking to develop skills in fast paced environment
A leading Biotech company with headquarters office in San Diego and production facilities in Asia focusing has a full time need for a […